De novo anti-HLA antibody responses after renal transplantation: Detection and clinical impact

Contributions to Nephrology

Volumn 162, Issue , 2009, Pages 87-98

  Seveso, Michela ^a   Bosio, Erika ^b   Ancona, Ermanno ^a,b,c   Cozzi, Emanuele ^a,b,c  

^a CORIT ^*  (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; HLA ANTIGEN; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; BLOOD; DONOR; GRAFT REJECTION; HUMAN; IMMUNOLOGY; KIDNEY; KIDNEY TRANSPLANTATION; PATHOLOGY; REVIEW;

ANTIBODY SPECIFICITY; COMPLEMENT C4B; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY; KIDNEY TRANSPLANTATION; PEPTIDE FRAGMENTS; TISSUE DONORS;

EID: 59849089691     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000170841     Document Type: Article

References (42)

1. Terasaki PI: Humoral theory of transplantation. Am J Transplant 2003;3:665.
2. Halloran P F, Schlaut J, Solez K, Srinivasa NS: The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992;53:550.
3. Davenport A, Younie ME, Parsons JE, Klouda PT: Development of cytotoxic antibodies following renal allograft transplantation is associated with reduced graft survival due to chronic vascular rejection. Nephrol Dial Transplant 1994;9:1315.
4. Abe M, Kawai T, Futatsuyama K, Tanabe K, Fuchinoue S, Teraoka S, Toma H, Ota K: Postoperative production of anti-donor antibody and chronic rejection in renal transplantation. Transplantation 1997;63:1616.
5. Lee PC, Terasaki PI, Takemoto SK, Lee PH, Hung CJ, Chen YL, Tsai A, Lei HY: All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002;74:1192.
6. Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RW: Post-transplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003;75:1034.
7. Lachmann N, Terasaki PI, Schonemann C: Donor-specific HLA antibodies in chronic renal allo-graft rejection: a prospective trial with a four-year follow-up. Clin Transpl 2006:171.
8. Terasaki PI, Ozawa M: Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004;4:438.
9. Terasaki PI, Ozawa M: Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 2005;80:1194.
10. Hourmant M, Cesbron-Gautier A, Terasaki PI, Mizutani K, Moreau A, Meurette A, Dantal J, Giral M, Blancho G, Cantarovich D, Karam G, Follea G, Soulillou J P, Bignon JD: Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005;16:2804.
11. Terasaki PI, Cai J: Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005;17:541-545.
12. Terasaki PI, Ozawa M, Castro R: Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007;7:408.
13. Piazza A, Poggi E, Ozzella G, Borrelli L, Scornajenghi A, Iaria G, Tisone G, Adorno D: Post-transplant donor-specific antibody production and graft outcome in kidney transplantation: results of 16-year monitoring by flow cytometry. Clin Transpl 2006:323.
14. Martin L, Guignier F, Mousson C, Rageot D, Justrabo E, Rifle G: Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 2003;76:395.
15. Heinemann FM, Roth I, Rebmann V, Arnold ML, Spriewald BM, Grosse-Wilde H: Characterization of anti-HLA antibodies eluted from explanted renal allografts. Clin Transpl 2006:371.
16. Kreijveld E, Hilbrands LB, van Berkel Y, Joosten I, Allebes W: The presence of donor-specific human leukocyte antigen antibodies does not preclude successful withdrawal of tacrolimus in stable renal transplant recipients. Transplantation 2007;84:1092.
17. Gebel HM, Bray RA, Nickerson P: Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003;3:1488.
18. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI: Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003;75:43.
19. Patel R, Terasaki PI: Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969;280:735.
20. Zachary AA, Klingman L, Thorne N, Smerglia AR, Teresi GA: Variations of the lymphocytotoxi-city test. An evaluation of sensitivity and specificity. Transplantation 1995;60:498.
21. Kao KJ, Scornik JC, Small SJ: Enzyme-linked immunoassay for anti-HLA antibodies - an alternative to panel studies by lymphocytotoxicity. Transplantation 1993;55:192.
22. Pei R, Wang G, Tarsitani C, Rojo S, Chen T, Takemura S, Liu A, Lee J: Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum Immunol 1998;59:313.
23. Gloor JM, Moore SB, Schneider BA, Degoey SR, Stegall MD: The effect of antithymocyte globulin on anti-human leukocyte antigen antibody detection assays. Transplantation 2007;84:258.
24. Lee PC, Ozawa M: Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. Clin Transpl 2007:219.
25. Martin LH, Calabi F, Lefebvre FA, Bilsland CA, Milstein C: Structure and expression of the human thymocyte antigens CD1a, CD1b, and CD1c. Proc Natl Acad Sci USA 1987;84:9189.
26. Campos E F, Tedesco-Silva H, Machado PG, Franco M, Medina-Pestana JO, Gerbase-DeLima M: Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006;6:2316.
27. Varnavidou-Nicolaidou A, Iniotaki-Theodoraki AG, Doxiadis II, Georgiou D, Patargias T, Stavropoulos-Giokas C, Kyriakides G: Expansion of humoral donor-specific alloreactivity after renal transplantation correlates with impaired graft outcome. Hum Immunol 2005;66:985.
28. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson I W, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M: Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008;8:753.
29. McKenna RM, Takemoto SK, Terasaki PI: Anti-HLA antibodies after solid organ transplantation. Transplantation 2000;69:319.
30. Worthington JE, Martin S, Dyer PA, Johnson RW: An association between posttransplant antibody production and renal transplant rejection. Transplant Proc 2001;33:475.
31. Mizutani K, Terasaki P, Rosen A, Esquenazi V, Miller J, Shih RN, Pei R, Ozawa M, Lee J: Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005;5:2265.
32. Scornik JC, Guerra G, Schold JD, Srinivas TR, Dragun D, Meier-Kriesche HU: Value of post-transplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant 2007;7:1808.
33. Heinemann FM, Roth I, Rebmann V, Arnold ML, Witzke O, Wilde B, Spriewald BM, Grosse-Wilde H: Immunoglobulin isotype-specific characterization of anti-human leukocyte antigen antibodies eluted from explanted renal allografts. Hum Immunol 2007;68:500.
34. Ozawa M, Rebellato LM, Terasaki PI, Tong A, Briley K P, Catrou P, Haisch CE: Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience. Clin Transpl 2006:265.
35. Mauiyyedi S, Pelle PD, Saidman S, Collins AB, Pascual M, Tolkoff-Rubin NE, Williams W W, Cosimi AA, Schneeberger EE, Colvin RB: Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001;12:574.
36. Colvin RB: Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007;18:1046.
37. Koch CA, Khalpey ZI, Platt JL: Accommodation: preventing injury in transplantation and disease. J Immunol 2004;172:5143.
38. Salama AD, Delikouras A, Pusey CD, Cook HT, Bhangal G, Lechler RI, Dorling A: Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001;1:260.
39. Kujovich JL: Thrombophilia and thrombotic problems in renal transplant patients. Transplantation 2004;77:959.
40. Le Bas-Bernardet S, Hourmant M, Coupel S, Bignon JD, Soulillou J P, Charreau B: Non-HLA-type endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am J Transplant 2003;3:167.
41. Narayanan K, Jaramillo A, Phelan DL, Mohanakumar T: Pre-exposure to subsaturating concentrations of HLA class I antibodies confers resistance to endothelial cells against antibody complement-mediated lysis by regulating Bad through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 2004;34:2303.
42. Jin Y P, Fishbein MC, Said J W, Jindra PT, Rajalingam R, Rozengurt E, Reed EF: Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol 2004;65:291.